Fungemia caused by an amphotericin B-resistant isolate of Sporothrix schenckii. Successful treatment with itraconazole.

A 58-year-old, alcoholic, diabetic man presented with multiple, ulcerated skin lesions and polymicrobial septicemia. Sporothrix schenckii was recovered from blood cultures and was resistant to amphotericin B by in vitro testing. Amphotericin B therapy failed, but the patient responded dramatically to itraconazole therapy, only to relapse 3 months after therapy was stopped. Reinstitution of itraconazole therapy has produced another dramatic response. This report is noteworthy for three reasons. First, to our knowledge, it represents only the second reported instance of fungemia with S schenckii that responded to medical therapy. Second, it illustrates that in vitro antifungal susceptibility tests may predict clinical infection response to drug therapy. Third, it suggests that itraconazole has significant promise in treating systemic sporotrichosis.
AuthorsJ H Baker, H C Goodpasture, H R Kuhns Jr, M G Rinaldi
JournalArchives of pathology & laboratory medicine (Arch Pathol Lab Med) Vol. 113 Issue 11 Pg. 1279-81 (Nov 1989) ISSN: 0003-9985 [Print] UNITED STATES
PMID2554844 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antifungal Agents
  • Itraconazole
  • Amphotericin B
  • Ketoconazole
  • Amphotericin B
  • Antifungal Agents (therapeutic use)
  • Drug Resistance, Microbial
  • Humans
  • Itraconazole
  • Ketoconazole (analogs & derivatives, therapeutic use)
  • Male
  • Middle Aged
  • Sepsis (drug therapy)
  • Sporothrix
  • Sporotrichosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: